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Abstract 
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, 
invariably relapses and acquires a multidrug chemoresistant phenotype that generally ren-
ders retreatment with first-line therapy both futile and counterproductive. This report pre-
sents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was 
restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) 
involving pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a 
partial response after only 4 cycles. The patient had received a platinum drug twice before, in 
2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for 
SCLC, suggesting that RRx-001 pretreatment may sensitize or resensitize refractory SCLC 
patients to first-line chemotherapy. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Small-cell lung cancer (SCLC) is a particularly aggressive form of lung cancer character-
ized by rapid doubling time, high growth fraction, and early dissemination [1]. The staging 
system for the disease incorporates a binary classification: limited-stage SCLC is confined to 
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one hemithorax while all other disease is categorized as extensive-stage SCLC [2]. Typically 
radio- and chemosensitive at the outset, the development of resistance even after initial re-
sponse is practically a fait accompli for extensive-stage SCLC, usually within the first year 
from diagnosis [3]. The predicted probability of the efficacy of second-line chemotherapy is 
based on response to first-line treatment; ‘sensitive’ disease, that is relapse beyond 60 or 90 
days after completion of first-line treatment, is associated with a better prognosis and sur-
vival outcome than ‘refractory’ disease, that is no response or relapse during ongoing first-
line treatment, and ‘resistant’ disease, that is progression within 60 or 90 days following 
first-line response [4]. 
The topoisomerase I inhibitor topotecan is approved in the United States and European 
Union only for second-line therapy of sensitive SCLC [5], while the synthetic anthracycline 
amrubicin is approved in Japan [6]. For refractory or resistant SCLC, no standard therapy is 
available. The overall survival with topotecan in the resistant/refractory population ranges 
from 4.7 to 5.7 months [7] while the response rate is <10% [8]. In addition to topotecan and 
amrubicin, cyclophosphamide, Adriamycin and vincristine (CAV) has been investigated with 
similarly poor overall survival, progression-free survival and response rates [9]. RRx-001 is 
a first-in-class systemically non-toxic [10] epi-immunotherapeutic agent [11] which pos-
sesses both radiosensitizing and chemosensitizing activity as well as radioprotective and 
chemoprotective properties [12, 13]; the molecule is under investigation as a tumor priming 
agent in an open-label phase II clinical trial called TRIPLE THREAT (NCT02489903), which 
involves treatment of SCLC, non-small-cell lung cancer (NSCLC) or platinum-refractory neu-
roendocrine tumors with RRx-001 until progression followed by sequential re-introduction 
of cisplatin or carboplatin and etoposide. In this report, the case of 77-year-old Caucasian 
male with extensive-stage refractory SCLC – so categorized because he initially relapsed 
during ongoing first-line treatment – who responded to retreatment with carboplatin/ 
etoposide after progression on RRx-001 monotherapy is presented. 
Case Presentation 
A 77-year-old Caucasian male with a 30-pack-year smoking history was diagnosed with 
a medically operable stage 1 NSCLC (squamous cell carcinoma) in 2000 and 2007, resulting 
in left upper and right upper lobectomies. In 2009 a CT revealed a new pulmonary nodule 
for which he received radiation and 7 cycles of adjuvant carboplatin and taxol. In 2015 a new 
mass on CT scan, biopsied with fine needle aspiration and fiberoptic bronchoscopy, estab-
lished a histological diagnosis of SCLC. 
In May and July 2015 the patient completed 4 cycles of cisplatin-etoposide with re-
sponse assessment every 2 cycles or 6 weeks. Despite a partial radiographic response at 
week 6, disease progression was observed on therapy during cycle 4 (week 12), which clas-
sified his disease as refractory. In November 2015 he was enrolled on the TRIPLE THREAT 
clinical trial and began weekly intravenous treatment with RRx-001. However, despite a 
marked symptomatic improvement, a restaging scan at week 6 demonstrated disease pro-
gression per RECIST v.1.1 which was suspicious for pseudoprogression [14], given the asso-
ciation of RRx-001 with transient tumor enlargement during initial scans followed by stabili-
zation or shrinkage. 
Nevertheless, on the basis of RECIST-defined progression, he was restarted on platinum 
doublets (carboplatin/etoposide) in December 2015. After 2 cycles of doublet therapy (week 
6), which was much better tolerated on this occasion than the first time he received it, a CT 
scan demonstrated around 30% tumor shrinkage, which met the criteria for a partial re-
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sponse. By week 12 (4 cycles) he developed neutropenia and therapy was interrupted. How-
ever, the restaging scan demonstrated a 58% reduction in the size of his tumors, confirming 
the partial response (fig. 1). 
Conclusion 
In the pantheon of the most difficult to treat metastatic malignancies, SCLC is on par 
with ovarian, brain, liver and pancreatic cancer in terms of its multidrug resistance [15] and 
consequent intractability to second-line therapies, including so-called targeted agents. Stag-
nant for more than three decades, the standard treatment for extensive-stage SCLC remains 
cisplatin and etoposide (PE); the exquisite initial chemosensitivity to PE belies the very poor 
prognosis after treatment with subsequent therapies. Even though PD-1 checkpoint inhibi-
tors may be poised to challenge the platinum hegemony and change the treatment landscape 
in SCLC as in NSCLC, the response rates to pembrolizumab in the phase Ib KEYNOTE-028 
trial [16] as well as nivolumab and nivolumab/ipilimumab in the phase I/II CheckMate 032 
trial are counterbalanced by concerns about increased autoimmune toxicities [17], given the 
association between SCLC and paraneoplastic disorders such as Lambert-Eaton myasthenic 
syndrome. 
A key oncologic treatment goal is to reverse the inevitable death trajectory of metastatic 
tumors to one of long-term survival while minimizing adverse effects. The promising strate-
gy of episensitization [18, 19], a hybrid term coined by Oronsky, Carter, Scicinski and Reid, 
which involves priming with a systemically non-toxic epigenetic agent like RRx-001 followed 
by rechallenge with formerly tried chemotherapies, represents a literal comeback both for 
the patient if the strategy is successful and the re-introduced first-line treatment. To date, 2 
out of 3 resistant/refractory SCLC patients enrolled in the TRIPLE THREAT trial have 
demonstrated responses to re-introduced platinum doublets, suggesting that the episensiti-
zation strategy may have the potential to yield promising clinical benefits. 
Statement of Ethics 
The patient described in this case report has given his informed consent as part of the 
TRIPLE THREAT clinical study (NCT02489903). This study protocol has been approved by 
the Walter Reed National Military Medical Center Institutional Review Board and the study 
conducted according to the Declaration of Helsinki principles. The patient gave written in-
formed consent. 
Disclosure Statement 
B.O., J.S. and S.C. are employees of EpicentRx, Inc. EpicentRx, Inc. provided funding for 
the study. 
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Fig. 1. CT scan images showing tumor shrinkage after re-exposure to platinum doublets. Left: At disease 
progression on the study drug RRx-001, prior to re-introduction of platinum (12/30/2015). Right: After 4 
cycles of platinum therapy (carboplatin/etoposide) (4/6/2016). Upper row: Decrease in size of the para-
tracheal lesion from 3.23 to 1.67 cm (–48%). Middle row: Disappearance of the right upper lobe lymph 
node lesion. Lower row: Decrease in size of the subtracheal lesion from 5.34 to 1.92 cm (–64%). 
 
